DCISionRT Enhances DCIS Risk Stratification Beyond Clincopathology
Patients reclassified to high-risk clinicopathology with DCISionRT saw an absolute reduction in IBR rates of 11.6%; from 17.7% to 6.1%.
Previous Post
FDA Approves Dordaviprone as First and Only Treatment for Aggressive Form of Glioma
Next Post
Use of GLP-1 RAs Associated With Increased Risk of NAION in Patients With Diabetes
📢
Advertisement
300x250 Banner
Recent Content
COPD Biologics: Early Treatment Insights
Pulmonology • 2 hours ago
Antihypertensive Medication Guidelines
Cardiology • 4 hours ago
Juvenile Arthritis Care Transition
Rheumatology • 6 hours ago